Published by Gbaf News
Posted on April 4, 2017
3 min readLast updated: January 21, 2026
Truffle Capital, a leading European venture capital firm aimed at creating young innovative companies and supporting their development, congratulates Symetis, leader in the field of percutaneous heart valve replacement solutions (TAVI), on its acquisition by Boston Scientific for $435 million[1]. Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.
Truffle Capital has been an historical investor of Symetis since its creation and has been involved in all its development stages: R&D, clinical development, industrialization, CE-marking and marketing in Europe (€35 million in sales in 2016).
Philippe Pouletty MD., co-founder and Managing Director of Truffle Capital said, “The revolution of minimally-invasive interventional medicine is gaining momentum. New bioprosthetic devices and implants which make the patients treatment procedures faster, more accurate and more convenient, have mainly been developed by start-upscompanies targeting disruptive innovations, Truffle Capital’s strategic focus“. He added, “Disruptive medical devices at a commercial stage or in clinical development are often better valued by corporate players than by thestock market. This is especially the case for structural heart and orthopedics devices.“
Truffle Capital is also co-founder and investor of Carmat (artificial heart), Epygon (mitral valve), Kephalios (adjustable mitral annuloplasty device) and Kardiosis (endoprosthesis for aortic aneurysm) in the field of cardiovascular devices; of Vexim (SpineJack® implant for vertebral fractures) in orthopedics; of Myopowers (artificial sphincter) in urology and of Théraclion (Echotherapy for tumors).
Truffle Capital, a leading European venture capital firm aimed at creating young innovative companies and supporting their development, congratulates Symetis, leader in the field of percutaneous heart valve replacement solutions (TAVI), on its acquisition by Boston Scientific for $435 million[1]. Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.
Truffle Capital has been an historical investor of Symetis since its creation and has been involved in all its development stages: R&D, clinical development, industrialization, CE-marking and marketing in Europe (€35 million in sales in 2016).
Philippe Pouletty MD., co-founder and Managing Director of Truffle Capital said, “The revolution of minimally-invasive interventional medicine is gaining momentum. New bioprosthetic devices and implants which make the patients treatment procedures faster, more accurate and more convenient, have mainly been developed by start-upscompanies targeting disruptive innovations, Truffle Capital’s strategic focus“. He added, “Disruptive medical devices at a commercial stage or in clinical development are often better valued by corporate players than by thestock market. This is especially the case for structural heart and orthopedics devices.“
Truffle Capital is also co-founder and investor of Carmat (artificial heart), Epygon (mitral valve), Kephalios (adjustable mitral annuloplasty device) and Kardiosis (endoprosthesis for aortic aneurysm) in the field of cardiovascular devices; of Vexim (SpineJack® implant for vertebral fractures) in orthopedics; of Myopowers (artificial sphincter) in urology and of Théraclion (Echotherapy for tumors).
Explore more articles in the Top Stories category
